Syngene International’s Board of Directors has approved the unaudited financial results for Q2 2026. Consolidated revenue reached ₹9,106 million, with profit after tax at ₹671 million. The Board meeting, held on November 05, 2025, also covered standalone results, showcasing a profit after tax of ₹662 million. The company highlighted key financial figures and ongoing strategic initiatives, as well as expansion plans in the US.
Financial Performance Highlights
Syngene International announced its unaudited standalone financial results for the quarter and half year ended September 30, 2025. Key figures from the consolidated results include:
- Revenue from operations: ₹9,106 million
- Profit before tax: ₹852 million
- Profit after tax: ₹671 million
The standalone results show a similar trend:
- Revenue from operations: ₹8,301 million
- Profit before tax: ₹842 million
- Profit after tax: ₹662 million
Operational Overview
Expenses for the quarter reflect investments in research, employee benefits, and other operational costs. Total expenses for the quarter reached ₹7,601 million (standalone) and ₹8,408 million (consolidated).
US Expansion
Syngene USA Inc., a wholly-owned subsidiary, acquired a biologics site in the USA, increasing the company’s bioreactor capacity to 50,000L. The cost incurred till March 31, 2025, reached ₹2,981 million, with additional pre-operating cost of ₹165 million accumulated during the six months ended September 30, 2025.
Equity and Dividends
The Board has allotted 402,439 equity shares to the Syngene Employees Welfare Trust. A final dividend of ₹1.25 per equity share was recommended and approved by shareholders during the recent Annual General Meeting.
Notable Financial Adjustments
During Q2 2026, ₹277 million (net of tax) was written off as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Also a claim of Rs 320 million was received from the insurance company for the loss of fixed assets in a fire incident on December 12, 2016.
Source: BSE
